342 related articles for article (PubMed ID: 9237325)
1. Activity of raloxifene in immature and ovariectomized rat uterotrophic assays.
Ashby J; Odum J; Foster JR
Regul Toxicol Pharmacol; 1997 Jun; 25(3):226-31. PubMed ID: 9237325
[TBL] [Abstract][Full Text] [Related]
2. Uterotrophic effects of tamoxifen, toremifene, and raloxifene do not predict endometrial cell proliferation in the ovariectomized CD1 mouse.
Carthew P; Edwards RE; Nolan BM
Toxicol Appl Pharmacol; 1999 Jul; 158(1):24-32. PubMed ID: 10387929
[TBL] [Abstract][Full Text] [Related]
3. Raloxifene (LY139481 HCI) prevents bone loss and reduces serum cholesterol without causing uterine hypertrophy in ovariectomized rats.
Black LJ; Sato M; Rowley ER; Magee DE; Bekele A; Williams DC; Cullinan GJ; Bendele R; Kauffman RF; Bensch WR
J Clin Invest; 1994 Jan; 93(1):63-9. PubMed ID: 8282823
[TBL] [Abstract][Full Text] [Related]
4. The rodent uterotrophic assay: critical protocol features, studies with nonyl phenols, and comparison with a yeast estrogenicity assay.
Odum J; Lefevre PA; Tittensor S; Paton D; Routledge EJ; Beresford NA; Sumpter JP; Ashby J
Regul Toxicol Pharmacol; 1997 Apr; 25(2):176-88. PubMed ID: 9185893
[TBL] [Abstract][Full Text] [Related]
5. Pharmacological actions of a novel, potent, tissue-selective benzopyran estrogen.
Galbiati E; Caruso PL; Amari G; Armani E; Ghirardi S; Delcanale M; Civelli M
J Pharmacol Exp Ther; 2002 Oct; 303(1):196-203. PubMed ID: 12235251
[TBL] [Abstract][Full Text] [Related]
6. Characterization of the pharmacologic profile of a standardized soy extract in the ovariectomized rat model of menopause: effects on bone, uterus, and lipid profile.
Gallo D; Zannoni GF; Apollonio P; Martinelli E; Ferlini C; Passetti G; Riva A; Morazzoni P; Bombardelli E; Scambia G
Menopause; 2005; 12(5):589-600. PubMed ID: 16145313
[TBL] [Abstract][Full Text] [Related]
7. Regulation of gene expression by 8-prenylnaringenin in uterus and liver of Wistar rats.
Diel P; Thomae RB; Caldarelli A; Zierau O; Kolba S; Schmidt S; Schwab P; Metz P; Vollmer G
Planta Med; 2004 Jan; 70(1):39-44. PubMed ID: 14765291
[TBL] [Abstract][Full Text] [Related]
8. Lasofoxifene enhances vaginal mucus formation without causing hypertrophy and increases estrogen receptor beta and androgen receptor in rats.
Wang XN; Simmons HA; Salatto CT; Cosgrove PG; Thompson DD
Menopause; 2006; 13(4):609-20. PubMed ID: 16837883
[TBL] [Abstract][Full Text] [Related]
9. Gene expression changes in the immature rat uterus: effects of uterotrophic and sub-uterotrophic doses of bisphenol A.
Ashby J; Odum J
Toxicol Sci; 2004 Dec; 82(2):458-67. PubMed ID: 15456929
[TBL] [Abstract][Full Text] [Related]
10. Benzophenone-induced estrogenic potency in ovariectomized rats.
Nakagawa Y; Tayama K
Arch Toxicol; 2002 Dec; 76(12):727-31. PubMed ID: 12451449
[TBL] [Abstract][Full Text] [Related]
11. Synthesis and pharmacology of conformationally restricted raloxifene analogues: highly potent selective estrogen receptor modulators.
Grese TA; Pennington LD; Sluka JP; Adrian MD; Cole HW; Fuson TR; Magee DE; Phillips DL; Rowley ER; Shetler PK; Short LL; Venugopalan M; Yang NN; Sato M; Glasebrook AL; Bryant HU
J Med Chem; 1998 Apr; 41(8):1272-83. PubMed ID: 9548817
[TBL] [Abstract][Full Text] [Related]
12. Examination of the in vitro and in vivo estrogenic activities of eight commercial phthalate esters.
Zacharewski TR; Meek MD; Clemons JH; Wu ZF; Fielden MR; Matthews JB
Toxicol Sci; 1998 Dec; 46(2):282-93. PubMed ID: 10048131
[TBL] [Abstract][Full Text] [Related]
13. An in vivo battery for identifying endocrine modulators that are estrogenic or dopamine regulators.
O'Connor JC; Cook JC; Craven SC; Van Pelt CS; Obourn JD
Fundam Appl Toxicol; 1996 Oct; 33(2):182-95. PubMed ID: 8921337
[TBL] [Abstract][Full Text] [Related]
14. Time-dependent changes in biochemical bone markers and serum cholesterol in ovariectomized rats: effects of raloxifene HCl, tamoxifen, estrogen, and alendronate.
Frolik CA; Bryant HU; Black EC; Magee DE; Chandrasekhar S
Bone; 1996 Jun; 18(6):621-7. PubMed ID: 8806005
[TBL] [Abstract][Full Text] [Related]
15. Structure-activity relationships of selective estrogen receptor modulators: modifications to the 2-arylbenzothiophene core of raloxifene.
Grese TA; Cho S; Finley DR; Godfrey AG; Jones CD; Lugar CW; Martin MJ; Matsumoto K; Pennington LD; Winter MA; Adrian MD; Cole HW; Magee DE; Phillips DL; Rowley ER; Short LL; Glasebrook AL; Bryant HU
J Med Chem; 1997 Jan; 40(2):146-67. PubMed ID: 9003514
[TBL] [Abstract][Full Text] [Related]
16. Lack of (anti-) androgenic or estrogenic effects of three pyrethroids (esfenvalerate, fenvalerate, and permethrin) in the Hershberger and uterotrophic assays.
Kunimatsu T; Yamada T; Ose K; Sunami O; Kamita Y; Okuno Y; Seki T; Nakatsuka I
Regul Toxicol Pharmacol; 2002 Apr; 35(2 Pt 1):227-37. PubMed ID: 12052007
[TBL] [Abstract][Full Text] [Related]
17. Diabetes modulates differentially creatine kinase-specific activity responsiveness to estradiol-17beta and to raloxifene in rat organs.
Somjen D; Shen M; Stern N; Mirsky N
J Cell Biochem; 2006 Sep; 99(1):133-9. PubMed ID: 16598752
[TBL] [Abstract][Full Text] [Related]
18. Comparative responses of three rat strains (DA/Han, Sprague-Dawley and Wistar) to treatment with environmental estrogens.
Diel P; Schmidt S; Vollmer G; Janning P; Upmeier A; Michna H; Bolt HM; Degen GH
Arch Toxicol; 2004 Apr; 78(4):183-93. PubMed ID: 14689164
[TBL] [Abstract][Full Text] [Related]
19. Validation of the intact rat weanling uterotrophic assay with notes on the formulation and analysis of the positive control chemical in vehicle.
Tyl RW; Marr MC; Brown SS; Dolbow EA; Myers CB
J Appl Toxicol; 2010 Oct; 30(7):694-8. PubMed ID: 20981862
[TBL] [Abstract][Full Text] [Related]
20. Contraceptive, estrogenic and anti-estrogenic potentials of methanolic root extract of Carpolobia lutea in rodents.
Ettebong EO; Nwafor PA; Ekpo M; Ajibesin KK
Pak J Pharm Sci; 2011 Oct; 24(4):445-9. PubMed ID: 21959803
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
